Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | RBP1 | P09455 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13055276 | 1.00 | CA1 (0.42) | CA1CA2CA4RBP1TSHR | |
| SCHEMBL12522654 | 1.00 | CA1 (0.42) | CA1CA2CA4RBP1TSHR | |
| SCHEMBL12522655 | 1.00 | CA1 (0.42) | CA1CA2CA4RBP1TSHR | |
| SCHEMBL12166974 | 1.00 | CA1 (0.42) | CA1CA2CA4RBP1TSHR | |
| SCHEMBL12522653 | 1.00 | CA1 (0.42) | CA1CA2CA4RBP1TSHR | |
| Methane SCHEMBL7165206 | 0.97 | CA1 (0.40) | CA1CA2CA4RBP1TSHR | |
| SCHEMBL13037447 | 0.83 | — | — | |
| SCHEMBL306725 | 0.83 | RBP1 (0.35) | CA1CA2CA4RBP1TSHR | |
| SCHEMBL12166658 | 0.78 | CA1 (0.37) | CA1CA2CA4 | |
| SCHEMBL10277182 | 0.74 | CA1 (0.42) | CA1CA2CA4TSHREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3470515-A2 | METHOD FOR THE BIOCATALYTIC CYCLISATION OF TERPENES AND CYCLASE MUTANTS WHICH CAN BE USED IN SAME | BASF SE (DE) | 2019-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CA1 4875/4885CA2 4275/4885CA4 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.